Amelioration of experimental acute pancreatitis with a potent platelet-activating factor antagonist

Publisher Website
Google Scholar
Abstract
The effect of a potent platelet‐activating factor (PAF) antagonist, BB‐882, on an experimental model of acute pancreatitis induced in male Wistar rats by a technique of microvascular ischaemia was studied. A single intraperitoneal injection of BB‐882 (5 mg/kg) 30 min after induction of the disease in 12 animals significantly reduced (P < 0.001) the rise in the level of serum amylase (mean 2477 (range 2100–3280) units/1) compared with that in 12 control animals (mean 3928 (range 2800–5900) units/1) and significantly improved (P < 0.001) the mean pancreatic histology score (5.0. (range 3–10) versus 12.3 (range 8–18) in controls). PAF is a biologically active ether phosphorylcholine synthesized in cell membranes and a potent inflammatory mediator. Pancreatic tissue levels of this compound are increased in experimental acute pancreatitis and pretreatment with PAF receptor antagonists can ameliorate the progression of this disease. BB–882 alters the early course of experimental pancreatitis and may have a clinical therapeutic role.

This publication has 20 references indexed in Scilit: